Published in Am J Cardiol on December 15, 2010
Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation (2012) 1.12
MicroRNA-208a increases myocardial fibrosis via endoglin in volume overloading heart. PLoS One (2014) 0.94
Endoglin: a critical mediator of cardiovascular health. Vasc Health Risk Manag (2013) 0.81
Reducing endoglin activity limits calcineurin and TRPC-6 expression and improves survival in a mouse model of right ventricular pressure overload. J Am Heart Assoc (2014) 0.80
Endothelial function and soluble endoglin in smokers with heart failure. Clin Cardiol (2011) 0.79
Can biomarkers help to diagnose early heart failure with preserved ejection fraction? Dis Markers (2015) 0.76
Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers. J Circ Biomark (2016) 0.75
The Role of Endoglin in Myocardial Fibrosis. Acta Cardiol Sin (2017) 0.75
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med (2007) 9.51
Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet (1994) 6.50
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Defective angiogenesis in mice lacking endoglin. Science (1999) 4.40
Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem (1992) 3.57
TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res (2004) 3.20
Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J (2004) 3.17
Death begets failure in the heart. J Clin Invest (2005) 2.72
Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain microvascular endothelial cells. Stroke (2003) 1.70
Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol (2005) 1.45
Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol (2003) 1.42
Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum (2002) 1.40
Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology (1994) 1.21
Endoglin upregulation during experimental renal interstitial fibrosis in mice. Hypertension (2002) 1.04
Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis. Biochim Biophys Acta (2002) 0.97
The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure. Eur J Heart Fail (2006) 0.87
Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma. Eur J Gastroenterol Hepatol (2007) 0.86
Examining potential therapies targeting myocardial fibrosis through the inhibition of transforming growth factor-beta 1. Cardiology (2007) 0.83
Endoglin (CD105) expression in the human heart throughout gestation: an immunohistochemical study. Reprod Sci (2008) 0.81
Role of endocardium in cardiac overloading and failure. Eur Heart J (1990) 0.81
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med (2004) 18.38
Statin-associated myopathy. JAMA (2003) 7.22
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50
Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol (2005) 5.39
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol (2007) 4.93
Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation (2003) 4.51
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Molecular and cellular basis of cardiovascular gender differences. Science (2005) 4.37
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (2011) 4.36
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78
Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J (2003) 3.73
Evidence-based guidelines for cardiovascular disease prevention in women. Circulation (2004) 3.39
Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation (2005) 3.34
Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA (2003) 3.25
Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest (2005) 3.22
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
Tackling heart failure in the twenty-first century. Nature (2008) 2.93
Systolic improvement and mechanical resynchronization does not require electrical synchrony in the dilated failing heart with left bundle-branch block. Circulation (2002) 2.88
Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res (2005) 2.79
Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol (2008) 2.77
Optimal left ventricular endocardial pacing sites for cardiac resynchronization therapy in patients with ischemic cardiomyopathy. J Am Coll Cardiol (2010) 2.66
Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc Imaging (2008) 2.64
Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol (2006) 2.61
Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med (2012) 2.59
Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension (2006) 2.59
Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol (2005) 2.53
High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation (2008) 2.47
Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science (2002) 2.45
Association between statin-associated myopathy and skeletal muscle damage. CMAJ (2009) 2.41
Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation (2005) 2.38
PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest (2005) 2.36
Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med (2003) 2.33
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A (2005) 2.25
L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA (2006) 2.24
Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol (2002) 2.22
The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation (2005) 2.19
Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res (2004) 2.19
Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function. Endocrinology (2014) 2.17
Effect of soy protein from differently processed products on cardiovascular disease risk factors and vascular endothelial function in hypercholesterolemic subjects. Am J Clin Nutr (2007) 2.15
Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res (2009) 2.11
Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA (2003) 2.10
Cardiac dyssynchrony analysis using circumferential versus longitudinal strain: implications for assessing cardiac resynchronization. Circulation (2005) 2.09
Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation (2009) 2.09
Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol (2007) 2.07
HRT and the young at heart. N Engl J Med (2007) 2.07
Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol (2005) 2.06
Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol (2007) 2.05
Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart. Circulation (2012) 2.05
Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res (2002) 2.05
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens (2007) 2.01
Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertension (2015) 2.01
Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions. J Am Coll Cardiol (2005) 1.98
Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol (2010) 1.95
Functional impact of rate irregularity in patients with heart failure and atrial fibrillation receiving cardiac resynchronization therapy. Eur Heart J (2004) 1.95
Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol (2007) 1.94
Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest (2011) 1.94
Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation (2011) 1.92
Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res (2005) 1.91
Assessment of peripheral vascular endothelial function in the ambulatory setting. Vasc Med (2007) 1.88
Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure. J Am Coll Cardiol (2013) 1.86
Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov (2007) 1.83
Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation (2008) 1.82
Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest (2009) 1.79
A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. Proc Natl Acad Sci U S A (2003) 1.78
Rapid estrogen receptor signaling is essential for the protective effects of estrogen against vascular injury. Circulation (2012) 1.78
Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc Natl Acad Sci U S A (2004) 1.77
Variation in estrogen-related genes and cross-sectional and longitudinal blood pressure in the Framingham Heart Study. J Hypertens (2005) 1.77
Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol (2009) 1.77
Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci U S A (2003) 1.76
Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res (2008) 1.76
17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res (2004) 1.74
Estrogen causes dynamic alterations in endothelial estrogen receptor expression. Circ Res (2002) 1.74
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause (2008) 1.74
ERbeta has nongenomic action in caveolae. Mol Endocrinol (2002) 1.73
cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res (2004) 1.73
Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. J Am Coll Cardiol (2012) 1.72
Hyperactive adverse mechanical stress responses in dystrophic heart are coupled to transient receptor potential canonical 6 and blocked by cGMP-protein kinase G modulation. Circ Res (2014) 1.70
Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res (2002) 1.70
Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies. Endocr Rev (2006) 1.68
Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol (2006) 1.68
Diastolic dysfunction is associated with myocardial viral load in simian immunodeficiency virus-infected macaques. AIDS (2012) 1.68
Reversal of global apoptosis and regional stress kinase activation by cardiac resynchronization. Circulation (2008) 1.67
Ventricular-vascular interaction in heart failure. Heart Fail Clin (2008) 1.67
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther (2009) 1.66
Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol (2010) 1.65
Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy. Circulation (2009) 1.63
Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins. Circulation (2013) 1.62
Clinical utility of endothelial function testing: ready for prime time? Circulation (2003) 1.62